Back to top

The first study of a candidate topical microbicide ever to be conducted in pregnant women, MTN-002 sought to understand whether microbicides being developed for women to protect themselves against HIV are safe if used during pregnancy. The Phase I study involved giving a single dose of tenofovir gel to 16 healthy, HIV-uninfected women hours before they gave birth by scheduled Cesarean section. Results, reported in May 2010, found only small amounts of drug were absorbed into the mother’s bloodstream, amniotic fluid and umbilical cord (fetal) blood; and no serious side effects in either the mothers or their newborns.


Researchers report results of first microbicide trial in pregnant women

Study indicates small amount of drug passes to fetus



MTN-002 Backgrounder



MTN-002 Q&A



See Also

MTN-002 Protocol


MTN-002 Study Page


Trial is first to see if HIV prevention gels are safe for pregnant women & their babies